Clinical trials located in

Bois-Guillaume

Bois-Guillaume city is located in France. Currently, 7 clinical trials are being conducted in this city.

Bois-Guillaume, a charming city in Normandy, France, seamlessly blends modern living with rich history. Perched atop a hill, it offers panoramic views of nearby Rouen. Historically, it was a strategic location during the Hundred Years’ War. Today, it’s known for its lush green spaces and vibrant community life. The city’s architecture is a mix of traditional Norman houses and contemporary buildings, reflecting its evolution over centuries. Bois-Guillaume also prides itself on its educational institutions and cultural events, making it a dynamic part of the Normandy region.

  • CT-EU-00111691

    SPI-62 as new drug for patients with ACTH-dependent Cushing’s syndrome

    This is a study focused on a new treatment option, SPI-62, for people struggling with ACTH-independent Cushing’s Syndrome. The main aim is to evaluate the efficacy and safety of SPI-62 in treating the condition.

    SPI-62 is a drug that works by inhibiting a specific enzyme in the body, potentially reducing excessive cortisol levels that contribute to the disease. During this study, participants will receive SPI-62 in oral tablet form. Dosing will vary, starting at a lower dose and potentially increasing depending on patient response and study requirements.

    The study has been designed as a Phase 2 trial, meaning that the primary focus is on understanding how well SPI-62 can treat the symptoms of hypercortisolism and what its safety profile is. Participants will be in the study for an extended period of time, with scheduled visits at baseline and then at 1, 3, 6, 9 and 12 months, followed by quarterly visits. These visits are crucial to monitor health status and treatment impact.

    One of the key aspects the researchers will be looking at is the change in HbA1c levels, a marker of blood sugar control, after both 6 and 12 weeks of treatment. This will help to understand whether SPI-62 can improve diabetes or the impaired glucose tolerance that often accompanies diabetes.

    • SPI-62- new potential medication for Cushing’s syndrome and Autonomous Cortisol Secretion
  • Comparison of different treatments for follicular lymphoma

    This study involves comparing two treatments for a condition known as follicular or marginal zone lymphoma, both of which are types of cancer affecting lymph cells. The first treatment combines zanubrutinib with an antibody called Anti-CD20, while the second treatment involves lenalidomide and rituximab. These treatments are intended for patients who have not responded or have stopped responding to conventional treatment. One of the primary objectives of the study is to determine which treatment is more effective in preventing the cancer from progressing, referred to as progression-free survival. Additionally, the study aims to assess the impact of these treatments on the patients’ quality of life, evaluating various aspects through questionnaires related to physical and emotional well-being, symptoms, and the ability to perform normal activities.

    • Zanubrutinib
    • Obinutuzumab
    • Lenalidomide
    • Rituximab
  • Study on dazostinag & pembrolizumab for advanced solid tumors

    The purpose of this study is to test a new drug called dazostinag. A study is being conducted to see whether this drug is helpful in adults with advanced forms of solid cancer. Some people are given dazostinag alone, while others are given it with another medicine called pembrolizumab. Scientists’ focus here is on finding out whether these drugs cause any side effects, and finding out what the maximum dose is that people can take without serious side effects. The study consists of two parts, including a dose escalation phase and a dose escalation phase. In the first part, the dose of dazostinag will be gradually increased, given alone or in combination with pembrolizumab. In the second part, Dazostinag will be tested with pembrolizumab and other anticancer drugs. This section will focus on patients with specific cancers that are difficult to remove or have spread to other parts of the body.

    • Dazostinag
    • Platinum
    • Pembrolizumab
    • 5-Fluorouracil
  • Examining the efficacy of Imlifidase in kidney transplant patients

    This study will test the drug imlifidase on patients who require a kidney transplant but have a condition that makes their body reject the new organ. In this study, the goal is to assess the effectiveness of imlifidase in facilitating acceptance of new organs among patients and evaluating the kidney’s functionality one year post-transplant. The patients, who must consent after being made aware of the risks, will be compared to two groups — one group who has recently received a transplant and another historical group from records of transplants. Imlifidase works by removing harmful antibodies quickly, allowing the body to accept the new organ. But after the transplant, these antibodies can come back. Therefore, patients in this study will be closely watched for any signs of their body rejecting the new organ, like through blood tests and organ checks at 6 months and 1 year.

    • Imlifidase
  • A study evaluating caplacizumab and immunosuppressive therapy in the treatment of thrombotic thrombocytopenic purpura

    This research study is all about testing a new treatment for a blood disorder called immune-mediated thrombotic thrombocytopenic purpura (iTTP). The treatment involves a medication named caplacizumab and some immune-weakening medicines, collectively known as Immunosuppressive Therapy (IST). If a patient gets involved in this study, they’ll be under observation for roughly six months. Assessments will be made every day during the hospital stay and once a week during ongoing treatment. In addition, there’ll be three visits made after treatment is completed, and two extra visits for certain patients may be needed.

    • Caplacizumab
  • Study of new drugs in acute lymphoblastic leukemia

    This clinical trial focuses on improving treatment strategies for acute lymphoblastic leukemia (ALL) in a diverse age group, from infants to young adults up to 45 years old. The study combines standard treatments with new drugs, for example, Inotuzumab Ozogamicin and Blinatumomab. The trial aims to tailor treatment to individual patient needs and reduce toxicity while maintaining treatment quality. By carefully monitoring event- and disease-free survival rates, as well as minimal residual disease responses, the trial aims to improve the standard of care for ALL and improve both survival outcomes and patient quality of life.

    • Inotuzumab Ozogamicin
    • 6-tioguanine
    • Blinatumomab
    • Imatinib
    • Dexamethasone
    • Vincristine
    • Doxorubicin
  • Exploring sacituzumab govitecan for HER2-negative breast cancer care

    This study is evaluating a new treatment for patients with a certain type of breast cancer (HER2-negative) who have not had a complete response to initial chemotherapy. Participants are randomly assigned to receive the investigational drug sacituzumab govitecan or a treatment of their physician’s choice, which may be another type of chemotherapy with capecitabinalub, carboplatin or cisplatin. The study is designed to compare the effectiveness of these approaches in preventing cancer recurrence. Patients may also receive hormone therapy if needed. Patients’ safety and response to treatment are being closely monitored throughout the study.

    • Sacituzumab govitecan
    • Carboplatin
    • Cisplatin
    • Capecitabine

See more clinical trials in other cities in France:

.